Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes?

Cancer Journal

Volumn 12, Issue 3, 2006, Pages 207-211

  Young, Shawn E ^a   Martinez, Steve R ^a   Faries, Mark B ^a   Essner, Richard ^a   Wanek, Leslie A ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Lymph node; Lymphadenectomy; Melanoma; Metastasis; Stage III; Surgery; Survival

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHI SQUARE TEST; CONTROLLED STUDY; FOLLOW UP; HUMAN; LOG RANK TEST; LONG TERM CARE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PRIORITY JOURNAL;

FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 33745175243     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200605000-00009     Document Type: Article

References (24)

1. Balch CM, Soong SJ, Atkins MB et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54:131-149.
2. Morton DL, Foshag LJ, Hoon DSB et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma cell vaccine. Ann Surg 1992;216:463-482.
3. Medalie N, Ackerman AB. Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now. Br J Dermatol 2004;151:298-307.
4. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-2751.
5. Creagan ET, Dalton RJ, Ahmann DL et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776-2783.
6. Eton O, Legha SS, Bedikian AY et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-2052.
7. Hauschild A, Weichenthal M, Balda BR et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 2003;21:2883-2888.
8. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
9. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-913.
10. Morton DL, Wanek L, Nizze JA et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991;214:491-499.
11. Allen PJ, Coit DG. The role of surgery for patients with metastatic melanoma. Curr Opin Oncol 2002;14:221-226.
12. Ollila DW, Hsueh EC, Stern SL et al. Metastasectomy for recurrent stage IV melanoma. J Surg Oncol 1999;71:209-213.
13. Rose DM, Essner R, Hughes TM et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 2001;136:950-955.
14. Wood TF, DiFronzo LA, Rose DM et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol 2001;8:658-662.
15. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
16. Morton DL, Hsueh EC, Essner R et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002;236:438-448.
17. Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
18. Cochran AJ, Wen DR, Morton DL. Management of the regional lymph nodes in patients with cutaneous malignant melanoma. World J Surg 1992;16:214-221.
19. Chan AD, Essner R, Wanek LA, Morton DL. Judging the therapeutic value of lymph node dissections for melanoma. J Am Coll Surg 2000;191:16-22.
20. Morton DL, Hoon DS, Cochran AJ et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003;238:538-549.
21. Morton DL, Thompson JF, Essner R et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453-463.
22. Cascinelli N, Morabito A, Santinami M et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998;351:793-796.
23. Balch CM, Soong S, Ross MI et al. Long-term results of a multiinstitutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000;7:87-97.
24. White RR, Stanley WE, Johnson JL et al. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002;235:879-887.